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Purpose: The aim of this study was to evaluate the effects of premedication with 
oral atenolol or enalapril, in combination with remifentanil under sevoflurane anes-
thesia, on intraoperative blood loss by achieving adequate deliberate hypotension 
(DH) during orthognathic surgery. Furthermore, we investigated the impact thereof 
on the amount of nitroglycerin (NTG) administered as an adjuvant agent. Materials 
and Methods: Seventy-three patients undergoing orthognathic surgery were ran-
domly allocated into one of three groups: an angiotensin converting enzyme inhibi-
tor group (Group A, n=24) with enalapril 10 mg, a β blocker group (Group B, 
n=24) with atenolol 25 mg, or a control group (Group C, n=25) with placebo. All pa-
tients were premedicated orally 1 h before the induction of anesthesia. NTG was the 
only adjuvant agent used to achieve DH when mean arterial blood pressure (MAP) 
was not controlled, despite the administration of the maximum remifentanil dose 
(0.3 μg kg-1min-1) with sevoflurane. Results: Seventy-two patients completed the 
study. Blood loss was significantly reduced in Group A, compared to Group C (ad-
justed p=0.045). Over the target range of MAP percentage during DH was signifi-
cantly higher in Group C than in Groups A and B (adjusted p-values=0.007 and 
0.006, respectively). The total amount of NTG administered was significantly less in 
Group A than Group C (adjusted p=0.015). Conclusion: Premedication with enala-
pril (10 mg) combined with remifentanil under sevoflurane anesthesia attenuated 
blood loss and achieved satisfactory DH during orthognathic surgery. Furthermore, 
the amount of NTG was reduced during the surgery. 
Key Words:   Atenolol, enalapril, premedication, blood loss, surgical, orthognathic 
surgery
INTRODUCTION
Various orofacial deformities have been corrected by orthognathic surgery. Howev-
er, due to bony bleeding at the incision site and the intricacy of the orofacial blood 
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atric illness, symptomatic asthma, or who were taking med-
ication for the treatment of a systemic disease were excluded. 
Randomization and allocation
The patients were randomly assigned to one of three groups 
using a computer-generated table of random numbers: the 
angiotensin converting enzyme (ACE) inhibitor group (Gr-
oup A, n=24) received 10mg of enalapril; the β-blocker 
group (Group B, n=24) received 25 mg of atenolol; and the 
control group (Group C, n=25) received a placebo tablet (vi-
tamin complex) 1 h before the induction of anesthesia. An 
anesthesiologist who was not involved in the study adminis-
tered the drug tablet directly into the mouths of the patients 
and monitored for enalapril side effects, including dry cough, 
diarrhea, headache, and nausea, or for the side effects of aten-
olol, such as chest pain, arrhythmia, bradycardia, orthostatic 
hypotension, confusion, tingling, numbness in the extremi-
ties, diarrhea, abdominal discomfort, nausea, and allergic re-
actions.10,11 The investigator, surgeons, attending anesthetist, 
patients, and recovery nurses were blinded to group allocation.
Procedure
Patients received 0.1 mg of glycopyrrolate intravenously for 
premedication. After arrival in the operating room, anesthe-
sia was induced with 2 mg kg-1 of propofol, 0.6 mg kg-1 of 
rocuronium, and 0.05‒0.1 µg kg-1 of remifentanil following 
non-invasive blood pressure monitoring, electrocardiogra-
phy, and measurement of oxygen saturation (SpO2). After 
nasotracheal intubation, the patients’ lungs were mechanical-
ly ventilated with a tidal volume of 8 mL kg-1 of ideal body 
weight at 50% air with oxygen, and the respiratory rate was 
adjusted to maintain the end-tidal carbon dioxide tension at 
35‒40 mm Hg. Radial artery catheterization was performed 
for continuous blood pressure monitoring and arterial blood 
gas analysis. The MAP and heart rate (HR) were monitored 
continuously. In addition, the cardiac index (CI) was mea-
sured by applying a FloTrac/VigilioTM system (Edwards Li-
fesciences, Irvine, CA, USA) via connection of the arterial 
cannulation for cardiac output monitoring. 
DH was induced at the mucosal incision until the surge-
on’s request after completion of the main surgical procedur-
es; to achieve a MAP within the target range of 55‒65 mm 
Hg, inhalation anesthesia was maintained with sevoflurane 
at an age-adjusted minimal alveolar concentration of 1.0, 
and remifentanil was infused until its dose increased to 0.3 
µg kg-1min-1.12,13 NTG was the only adjuvant agent used to 
achieve DH when MAP was not controlled, despite the admin-
vessels, orthognathic surgery can involve significant intra-
operative bleeding.1,2 Further, intraoperative bleeding in-
creases patient morbidity and mortality rates by extending 
surgical duration and time under anesthesia, as well as the 
amounts of blood transfusion required during surgery.3 
Since the 1950s, deliberate hypotension (DH) has been 
used as an alternate method in maxillofacial surgeries to re-
duce blood loss and the need for a transfusion during sur-
gery, as well as to improve the quality of the operative field 
through a reduction in mean arterial blood pressure (MAP).4,5 
In order to achieve DH, various agents, including sodium 
nitroprusside (SNP), nitroglycerin (NTG), and inhalation 
anesthetics have been successfully employed.6,7 
Nevertheless, reflex tachycardia, caused by the direct pe-
ripheral vasodilation effects of SNP, increases myocardial 
oxygen demand and makes the control of blood pressure 
difficult.6,8,9 Also, NTG is not as effective as SNP in reduc-
ing bleeding after achieving adequate DH, despite the fact 
that NTG has a better benefit/risk ratio than SNP.6 While the 
use of inhalational anesthetic drugs facilitates the successful 
achievement of DH, high concentrations of anesthetic agents 
are required to achieve adequate DH, which can lead to liver 
or kidney toxicity.6
In this randomized, double-blind, placebo-controlled 
study, we hypothesized that preoperative administration of 
oral atenolol or enalapril, in combination with remifentanil 
under sevoflurane anesthesia, would reduce intraoperative 
blood loss by achieving adequate DH in orthognathic sur-
gery. Furthermore, we evaluated the effects thereof on the 
amount of NTG administered as an adjuvant agent.
MATERIALS AND METHODS
Study design
This study was approved by the Institutional Review Board 
and Hospital Research Ethics Committee of Severance Hos-
pital, Yonsei University Health System, Seoul, Korea (4-
2012-0422) and was registered with the Clinical Research 
Information Service (registration number NCT 01839253). 
Informed consent was obtained from 73 patients (American 
Society of Anesthesiologists I‒II physical status, aged 
18‒29 years) who were to undergo orthognathic surgery be-
tween April 2013 and March 2014. Patients with hyperten-
sive disease, previous treatment with diuretics or hyperten-
sive drugs, coronary artery diseases, chronic renal failure, 
hepatic failure, drug hypersensitivity, neurological or psychi-
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alysis of non-normally distributed phenylephrine data was 
performed using the Kruskal-Wallis test. Chi-square test or 
Fisher’s exact test was used to analyze categorical variables. 
All p-values<0.05 were regarded as statistically significant. 
RESULTS
 
A total 75 patients were accessed for eligibility, and two pa-
tients with previous cardiac surgery and hypertension were 
excluded. Seventy-three patients were randomized into three 
groups. One patient in Group A was excluded due to a ch-
ange in the surgical plan. The remaining 72 patients complet-
ed the study without any complications (Fig. 1). Patients un-
istration of the maximum remifentanil dose (0.3 μg kg-1 min-1) 
with sevoflurane. Additionally, we calculated the target range 
of MAP percentage during DH. An over target range of 
MAP percentage was considered as the period in which the 
MAP was >65 mm Hg, while an under target range of MAP 
percentage was the period in which the MAP was <55 mm 
Hg. All ranges of MAP percentage were calculated using 
the 1-min interval of MAP by Philips monitoring device. 
Further, hematocrit (Hct) was maintained at >27% through-
out the surgery. 
Intraoperative fluid amounts, urine output, and blood loss 
were recorded hourly. Blood loss was estimated by measur-
ing suction bottle drainage, surgical drapes, and by weighing 
gauze sponges. Intraoperative fluid was maintained using 
Lactated Ringer’s Solution at a constant rate of 5‒10 mL kg-1 
h-1. When blood loss exceeded 300 mL, 6% hydroxyethyl 
starch solutions (Voluven, Fresinius Kabi, Bad Homberg, 
Germany) was administered at a 1:1 ratio, and if Hct was 
<27%, a transfusion was initiated. Hypotension (MAP<55 
mm Hg) was treated with 10 µg of intravenous phenyleph-
rine. At the time of mucosal suturing, 1 µg kg-1 of fentanyl 
and 0.3 mg of ramosetron were administered to all patients 
for postoperative pain and as an antiemetic, respectively. A 
blinded investigator monitored patient hemodynamics and 
any adverse effects during postoperative 24 hours. 
Statistical analysis
Sample sizes were calculated based on a previous study,13 
in which the mean±SD difference of intraoperative blood 
loss in the hypotensive group was 454.0±211.3 mL, and the 
corresponding value for the control group was 755.3±334.6 
mL. In order to detect 301.3 mL of blood loss between the 
three groups (α=0.05, power=80%), 22 patients were required 
for each group. Considering a 10% dropout rate, 25 patients 
were recruited for each group. 
All statistical analyses were performed using IBM SPSS 
Statistics 20.0 (SPSS Inc., Chicago, IL, USA). Continuous 
variables and categorical variables were presented as the 
mean±SD and numbers, respectively. Parametric data were 
analyzed with one-way analysis of variance with Bonferro-
ni correction for multiple comparisons. The MAP, HR, and 
CI values were analyzed using a linear mixed model at 11 
separate time points (Table 1). Differences over time among 
the three groups were analyzed using a group by time inter-
action. When statistical significances were detected in the re-
peated measures, post-hoc analyses using Bonferroni cor-
rection for multiple comparisons were performed. The an-
Table 1. Time Points for Hemodynamic Parameter Measure-
ments
Time point Event
T0 Baseline before premedication 
T1 Before induction of anesthesia after premedication 
T2 Just after induction of anesthesia 
T3 30 min after the induction of DH 
T4 60 min after the induction of DH 
T5 90 min after the induction of DH 
T6 120 min after the induction of DH 
T7 5 min after the end of DH
T8 Immediately after extubation in the operating room 
T9 60 min after extubation in the PACU 
T10
60 min after discharge from the PACU in the 
  admission room
DH, deliberate hypotension; PACU, post anesthetic care unit.
Analysed (n=23)
Excluded from 
analysis (n=1)
Lost to follow up
(n=1)
Allocated Group A
(n=24)
Analysed (n=24)
Excluded from 
analysis (n=0)
Lost to follow up
(n=0)
Allocated Group B
(n=24)
Randomized
(n=73)
Assessed for
eligibility (n=75)
Excluded (n=2)
Not meeting 
inclusion
Analysed (n=25)
Excluded from 
analysis (n=0)
Lost to follow up
(n=0)
Allocated Group C
(n=25)
Fig. 1. CONSORT flow diagram. Group A, angiotensin converting enzyme 
inhibitor group; Group B, β-blocker group; Group C, control group.
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ues=0.007 and 0.006, respectively). In addition, the amount 
of NTG used during DH was less in Group A than Group C 
(adjusted p=0.015). There was no difference in the amount 
of remifentanil administered during DH among the three 
groups. Similarly, despite the fact that Group A required more 
phenylephrine than the other groups, the difference was not 
statistically significant. 
Hemodynamic changes at each time point are shown in 
Figs. 2 and 3. Significant differences over time in MAP were 
observed among the three groups, following analysis using 
a linear mixed model (p=0.0016) (Fig. 2). The results of 
Bonferroni post-hoc comparisons for repeated measures in-
dicated a pattern of significant differences in MAP at T1 be-
tween Group A and C (adjusted p=0.0561). In addition, MAP 
at T1 was statistically lower in Group B than Group C (ad-
justed p<0.001), and MAP at T7 was significantly higher in 
Group C than Group A (adjusted p<0.001). HR and CI val-
ues are shown in Fig. 3. There were significant overall differ-
ences in the HR values among the three groups, regardless 
of time, following analysis using a linear mixed model. The 
results of post-hoc analysis using Bonferroni correction in-
dicated that HR of Group B was significantly lower than that 
derwent simultaneous bimaxillary orthognathic surgery, in-
cluding Lefort I osteotomy and mandibular ramus osteotomy. 
Additionally, 17 patients in Group A, 15 patients in Group B, 
and 14 patients in Group C underwent additional genioplas-
ty. The differences in the number of patients in the groups 
that underwent additional genioplasty were not statistically 
significant.
Demographic data are shown in Table 2. The weights and 
body mass indices were significantly different among the 
three groups. Further, the results indicated that the values for 
both measurements were higher in Group C than in Group 
B (adjusted p=0.010). There was no significant difference 
in preoperative and postoperative Hb levels between the 
three groups. 
Intraoperative data are presented in Table 3. The total du-
ration of surgery was similar among the groups; however, 
there was a significant difference in the duration of DH 
among the three groups. The duration of DH in Group C was 
longer than that of Group B following post-hoc analysis 
with Bonferroni correction (adjusted p=0.026). Furthermore, 
the over target range percentage during DH was significantly 
higher in Group C than in Groups A and B (adjusted p-val-
Table 2. Patient Characteristics According to Preoperative Agent
Group A (n=23) Group B (n=24) Group C (n=25) p value
Gender (M/F) 11/12 8/16 15/10 0.194
Age (yrs) 22.6±3.5 21.6±3.1 21.7±2.9 0.475
Weight (kg) 60.5±10.9 57.4±9.7 66.8±11.9 0.011*
Height (cm) 168.2±9.7 166.2±7.8 169.3±7.1 0.401
BMI (kg/m2) 21.3±2.3 20.8±2.8 23.2±3.3 0.008*
ASA physical status I/II 21/2 24/0 23/2 0.457
Preoperative Hct (%) 34.96±3.5 34.08±3.1 36.28±3.4 0.082
BMI, body mass index; ASA, American Society of Anesthesiologists; Hct, hematocrit; A, angiotensin converting enzyme inhibitor; B, β-blocker; C, control.
Data are presented as means±standard deviation or as numbers.
*p<0.05.
Table 3. Intraoperative Data on DH According to Preoperative Agent
Group A (n=23) Group B (n=24) Group C (n=25) p value
Duration of surgery (min) 276.7±63 264.1±64.8 271.0±52 0.769
Duration of DH (min) 179.1±57.4 155.8±40.1 192.0±44.1 0.032*
Over target range percentage during DH (%) 13.9±11.3 13.8±7.0 23.2±11.7 0.002*
Target range percentage during DH (%) 74.4±10.5 76.0±12.5 68.7±12.1 0.079
Under target range percentage during DH (%) 11.6±9.4 10.3±7.3 8.1±7.5 0.321
Remifentanil amounts during DH (µg/kg/min) 0.07±0.12 0.06±0.10 0.06±0.12 0.927
NTG amounts during DH (µg/kg/min) 3.2±12.7 6.2±16.9 18.4±23.7 0.012*
Patients administered phenylephrine during DH (n) 6 5 4 0.668
Phenylephrine amounts during DH (µg) 0 (0‒300) 0 (0‒70)  (0‒50) 0.634
DH, deliberate hypotension; NTG, nitroglycerin; A, angiotensin converting enzyme inhibitor; B, β-blocker; C, control.
Data are presented as means±standard deviation, numbers or median range.
*p<0.05.
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Fig. 3. (A) Heart rate (HR) and (B) cardiac index (CI) in Groups A, B, and C at each time point, as shown in Table 1. Analysis using a linear mixed model indi-
cated significant overall differences among the three groups, regardless of time. After post-hoc analysis with Bonferroni correction, the HR of Group B was 
significantly lower than that of Group C (adjusted p=0.0213). Furthermore, there was no significant difference in CI among the three groups at any of the time 
points analyzed. Group A, angiotensin converting enzyme inhibitor group; Group B, β-blocker group; Group C, control group. *Adjusted p<0.05.
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the most commonly used hypotensive agents.6 However, 
intraoperative administration of SNP can trigger direct vaso-
dilation effects that in turn cause a reduction in venous re-
turn. Peripheral vasodilatation results in baroreceptor-induc-
ed reflex tachycardia and an increase in myocardial con-
tractility. The sympathetic and renin-angiotensin systems 
are also activated, and are responsible for the rebound hyper-
tension that causes perioperative hemodynamic derange-
ment.6 The endocrine responses related to NTG-induced 
hypotension are contradictory in terms of plasma catechol-
amine levels, most likely due to differences in the magni-
tude of the surgical stress, blood loss, and the level and du-
ration of hypotension.18 If adequate hypotension levels are 
not obtained during surgery, intraoperative blood loss can be 
more severe. A number of previous studies have proposed 
premedication with a β-blocker in combination with SNP 
during DH for the reduction of reflex tachycardia and re-
bound hypertension.8,19,20 However, to the best of our knowl-
edge, no prior studies have investigated the impact of a pre-
operative oral β-blocker or ACE inhibitor administration on 
the intraoperative blood loss or achievement of adequate 
DH when combined with intraoperative NTG as an adjuvant 
agent under balanced anesthesia. 
The primary objective of this study was to evaluate wheth-
er preoperative treatment with a β-blocker or ACE inhibitor 
could significantly reduce total blood loss during surgery. 
The intraoperative blood loss was significantly lower in 
Group A (720±254.4 mL) than Group C (1030±555.1 mL). 
Although Group B exhibited an average blood loss of 793± 
418.1 mL, which was lower than that in in Group C, the dif-
ference was not statistically significant. Therefore, premedi-
cation with oral enalapril under general anesthesia could at-
tenuate blood loss during orthognathic surgery. 
In the present study, the duration of DH was significantly 
longer in Group C than Group B, despite the fact that there 
were no significant differences in the duration of surgery. 
of Group C (adjusted p=0.0213). Furthermore, no signifi-
cant differences were detected in CI among the three groups 
at any time point. 
Total intraoperative blood loss was significantly less in 
Group A than in Group C (adjusted p=0.045) (Table 4). How-
ever, there was no significant difference in the amount of 
intraoperative autologous blood transfusion among the three 
groups. Total volume of fluid administered and urine output 
were comparable among the groups. No patients suffered 
from hemodynamic instability or any other complications. 
DISCUSSION
The results of the current study indicated that preoperative 
medication with 10 mg of enalapril attenuated blood loss and 
achieved satisfactory DH during orthognathic surgery un-
der balanced anesthesia with remifentanil and sevoflurane, 
while premedication with 25 mg of atenolol did not signifi-
cantly reduce intraoperative blood loss. Further, enalapril 
was effective in reducing the amount of NTG adjuvant agent 
administered during the surgery. 
Currently, DH is used for surgeries that require the transfu-
sion of a large amount of blood14 and for attaining a blood-
less surgical field.6 Additionally, a number of previous re-
ports have indicated that DH is likely to cause a significant 
reduction in intraoperative blood loss.2,15,16 In order to in-
duce DH under general anesthesia, various different combi-
nations of agents and primary inhalation anesthetics have 
been used.17
Inhalation agents produce vasodilatory effects in a dose 
dependent manner, and can affect intraoperative blood loss 
due to associated pharmacologic effects.11 Also, when used 
alone, high concentrations of inhalation anesthetics are need-
ed to achieve adequate hypotension, which can lead to liver 
or kidney toxicity.6 Vasodilators, such as SNP and NTG, are 
Table 4. Intraoperative Blood Loss, Fluid Amounts, and Urine Output According to Preoperative Agent 
Group A (n=23) Group B (n=24) Group C (n=25) p value
Intraoperative bleeding (mL) 720±254.4 793±418.1 1030±555.1 0.038*
Intraoperative autologous blood transfusion (pack) 0.35±0.57 0.38±0.65 0.60±0.91 0.421
Crystalloid (mL) 1743.5±469.8 1737.5±504.8 1744±565.6 0.999
Colloid (mL) 647.8±354.0 702.1±469.9 734.0±387.5 0.762
Total fluid (mL) 2391.3±685.1 2439.6±666.8 2478.0±825.6 0.911
Total urine output (mL) 588.0±389.8 389.8±165 540.4±347.1 0.085
The length of postoperative hospital stay (days) 3.26±0.54 3.33±0.57 3.36±0.70 0.845
A, angiotensin converting enzyme inhibitor; B, β-blocker; C, control.
Data are presented as means±standard deviation.
*p<0.05. 
Na Young Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 56   Number 4   July 20151120
with SNP, are slower; thus, NTG is not as effective for ach-
ieving adequate DH.6 Accordingly, other adjuvant agents 
may be required especially in young patients.23 In the present 
study, NTG was only infused when the target range blood 
pressure was not achieved using anesthetic agents alone. 
Group A required the use of significantly lower amounts of 
NTG than Group C. This result may have clinical signifi-
cance, as premedication with enalapril not only caused sig-
nificant attenuation of intraoperative blood loss, but also re-
sulted in decreased reliance on NTG to achieve adequate 
DH, which could lead to a reduction in adverse NTG effects. 
However, there were no significant differences in the mean 
amounts of remifentanil administered during DH among the 
three groups (μg kg-1min-1). Remifentanil was used to con-
trol the target range MAP by incremental adjustment of the 
dose to 0.3 μg kg-1min-1. NTG was added only when MAP 
was not controlled despite administration of the maximum 
remifentanil dose to stabilize MAP during DH. However, 
administration of the maximum remifentanil dose (0.3 μg 
kg-1min-1) was not required throughout the DH period, 
which explains why there were no statistically significant dif-
ferences among the three groups in the mean amounts of 
remifentanil administered during DH (0.06‒0.07 μg kg-1 
min-1). In addition, there was no statistical difference in the 
number of patients who were administered phenylephrine 
and phenylephrine amounts during DH among the three 
groups, even though Group A required more phenylephrine. 
The current study has some limitations. Despite no dif-
ferences in the lengths of the postoperative hospital stay 
among the three groups, postoperative edema and recovery 
time should have been evaluated, and evaluation on the qual-
ity of the surgical field during DH should have been rated 
by the surgeon. In addition, there were no statistical differ-
ences among the three groups in the amount of intraopera-
tive autologous blood transfusions, even though blood loss 
was significantly greater in Group C than in the other groups. 
Likely explanations include the possibility that some pa-
tients became anemic following pre-operative autologous 
donation, and that Hct dropped below 27% in those patients 
without severe bleeding. Accordingly, the fact that preoper-
ative Hct in Group C was higher than in Groups A and B, 
despite a lack of statistically significant differences, might 
have affected the amounts of intraoperative blood transfu-
sion required. Lastly, it is difficult to confirm that the doses 
of both drugs were equivalent, even though the doses were 
the same as those used in previous studies that compared the 
efficacy of enalapril and atenolol.24,25 Consequently, poten-
This may be because blood pressure in Group C increased 
immediately after the end of DH. At this time, 4 patients in 
Group C developed persistent oozing and bleeding due to 
the acute elevation of MAP; DH was restarted upon the sur-
geon’s request and the remainder of the procedure was per-
formed while DH was maintained. This indirectly implies 
that the surgical time during DH was prolonged due to the 
poor quality of the operative field. In addition, over target 
range percentage was significantly higher in Group C than 
in the other groups. Despite the lack of statistical significanc-
es, the target range percentage was the lowest in Group C, 
and the under target range percentage was the highest in 
Group A. In regards to hemodynamic changes, the target 
range for DH was 55‒65 mm Hg, because DH should not 
adversely affect the blood supply to vital organs and end-or-
gan perfusion and tissue oxygenation must be maintain-
ed.12,13 No severe hemodynamic instability was noted in ei-
ther group. The MAPs after premedication exhibited a 
significantly lower pattern in the premedication groups com-
pared to the control group: MAP at T1 time point (before 
induction of anesthesia after premedication) exhibited a sig-
nificantly lower pattern between Groups A and C. Further, 
even after post-hoc analysis, MAP at T1 was significantly 
lower in Group B than in Group C. However, there were no 
statistical differences among the three groups in the frequen-
cy of hypotension after induction of anesthesia (T2). In ad-
dition, MAP after termination of DH tended to be higher in 
Group C than the premedication groups: MAP at T7 (5 min 
after the end of DH) was significantly higher in Group C 
than Group A, even after post-hoc analysis. Enalapril may be 
a more suitable premedication agent to stabilize MAP after 
the end of DH and postoperative blood pressure, because of 
its pharmacodynamic profile.21 Acute elevation of MAP at 
the end of DH may increase the risk of re-bleeding, thus 
stabilization on the MAP of post-DH would be clinically 
beneficial. Also, there were no statistically significant differ-
ences among three groups in the HR and CI before and af-
ter premedication, as well as at the induction of anesthesia. 
Administration of NTG causes nonspecific, direct vaso-
dilation of venous capacitance vessels, and incidental vaso-
dilation in arteries.22 NTG also increases venous blood vol-
ume and decreases venous return, which consequently 
results in a proportional reduction in cardiac output. Since to-
tal blood volume can affect decreases in blood pressure, an 
excessive drop in blood pressure could occur in patients with 
a low blood volume, and coronary blood flow could be com-
promised. In addition, responses to NTG, when compared 
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tial differences in the drug doses might explain why the re-
duction in blood loss achieved with atenolol was not statis-
tically significant. Further efforts should be made to assess 
factors, such as patient recovery time and surgical field rat-
ing, as well as to identify other potential influencing factors. 
In conclusion, while premedication with 25 mg of ateno-
lol did not significantly reduce intraoperative blood loss, 
preoperative administration of 10 mg of enalapril attenuat-
ed blood loss and achieved satisfactory DH during orthog-
nathic surgery under balanced anesthesia with remifentanil 
and sevoflurane. Furthermore, preoperative treatment with 
enalapril led to a reduction in the amount of NTG adjuvant 
agent required during surgery. 
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